Cargando…

Antidiabetic effects of novel ellagic acid nanoformulation: Insulin-secreting and anti-apoptosis effects

Antioxidants are one of the effective treatment lines in managing type 2 diabetes (typ2diab) and its complications. Nanoformulations could help in ameliorating the oral bioavailability and biocompatibility properties. Ellagic acid (Ella) is a natural antioxidant compound commonly present in fruits....

Descripción completa

Detalles Bibliográficos
Autores principales: Harakeh, Steve, Almuhayawi, Mohammed, Jaouni, Soad Al, Almasaudi, Saad, Hassan, Saber, Amri, Turki Al, Azhar, Najiah, Abd-Allah, Elham, Ali, Soad, El-Shitany, Nagla, Mousa, Shaker A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715050/
https://www.ncbi.nlm.nih.gov/pubmed/33304158
http://dx.doi.org/10.1016/j.sjbs.2020.09.060
_version_ 1783618863511896064
author Harakeh, Steve
Almuhayawi, Mohammed
Jaouni, Soad Al
Almasaudi, Saad
Hassan, Saber
Amri, Turki Al
Azhar, Najiah
Abd-Allah, Elham
Ali, Soad
El-Shitany, Nagla
Mousa, Shaker A.
author_facet Harakeh, Steve
Almuhayawi, Mohammed
Jaouni, Soad Al
Almasaudi, Saad
Hassan, Saber
Amri, Turki Al
Azhar, Najiah
Abd-Allah, Elham
Ali, Soad
El-Shitany, Nagla
Mousa, Shaker A.
author_sort Harakeh, Steve
collection PubMed
description Antioxidants are one of the effective treatment lines in managing type 2 diabetes (typ2diab) and its complications. Nanoformulations could help in ameliorating the oral bioavailability and biocompatibility properties. Ellagic acid (Ella) is a natural antioxidant compound commonly present in fruits. This study examined the effect Ella nanoparticles (Ella NPs) alone and combined with metformin, the standard antidiabetic drug, on controlling blood glucose in typ2diab. Forty-eight adult Sprague-Dawley rats were used in this study. Except for the control group that was fed a regular pellet diet, all animals were fed a high-fat diet (HFD) for 9 weeks. For the last 4 weeks, rats were injected with streptozotocin (35 mg/kg). Then the rats were randomized into 8 groups: control, HFD, diabetic, Ella, Ella + metformin, Ella NPs, and Ella NPs + metformin. Data showed that Ella NPs improved blood glucose levels and the body weights of diabetic rats throughout all the weeks of the experiment whereas effects of the regular Ella were limited to the last two weeks of the treatment. Additionally, data demonstrated that the antidiabetic action of Ella NPs and its effective duration were similar to metformin. Ella NPs led to a lowering effect on lipid profile markers (total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL), and very-low-density lipoprotein (VLDL)), superior to the regular Ella, which reduced only TG and VLDL. Results of the pathological examination showed improved number and activity of beta islets in all treatment groups. The most enhanced islets were in the Ella NPs and metformin group. The different treatments decreased caspase 3 and increased insulin gene expression, and the effect was superior in the Ella NPs and metformin group. The results of this study confirmed that Ella could manage typ2diab by lowering glucose and lipid levels and improving body weight with the superiority of Ella NPs. The mechanisms behind these effects are inhibition of beta-cell apoptosis and stimulation of insulin production.
format Online
Article
Text
id pubmed-7715050
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-77150502020-12-09 Antidiabetic effects of novel ellagic acid nanoformulation: Insulin-secreting and anti-apoptosis effects Harakeh, Steve Almuhayawi, Mohammed Jaouni, Soad Al Almasaudi, Saad Hassan, Saber Amri, Turki Al Azhar, Najiah Abd-Allah, Elham Ali, Soad El-Shitany, Nagla Mousa, Shaker A. Saudi J Biol Sci Original Article Antioxidants are one of the effective treatment lines in managing type 2 diabetes (typ2diab) and its complications. Nanoformulations could help in ameliorating the oral bioavailability and biocompatibility properties. Ellagic acid (Ella) is a natural antioxidant compound commonly present in fruits. This study examined the effect Ella nanoparticles (Ella NPs) alone and combined with metformin, the standard antidiabetic drug, on controlling blood glucose in typ2diab. Forty-eight adult Sprague-Dawley rats were used in this study. Except for the control group that was fed a regular pellet diet, all animals were fed a high-fat diet (HFD) for 9 weeks. For the last 4 weeks, rats were injected with streptozotocin (35 mg/kg). Then the rats were randomized into 8 groups: control, HFD, diabetic, Ella, Ella + metformin, Ella NPs, and Ella NPs + metformin. Data showed that Ella NPs improved blood glucose levels and the body weights of diabetic rats throughout all the weeks of the experiment whereas effects of the regular Ella were limited to the last two weeks of the treatment. Additionally, data demonstrated that the antidiabetic action of Ella NPs and its effective duration were similar to metformin. Ella NPs led to a lowering effect on lipid profile markers (total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL), and very-low-density lipoprotein (VLDL)), superior to the regular Ella, which reduced only TG and VLDL. Results of the pathological examination showed improved number and activity of beta islets in all treatment groups. The most enhanced islets were in the Ella NPs and metformin group. The different treatments decreased caspase 3 and increased insulin gene expression, and the effect was superior in the Ella NPs and metformin group. The results of this study confirmed that Ella could manage typ2diab by lowering glucose and lipid levels and improving body weight with the superiority of Ella NPs. The mechanisms behind these effects are inhibition of beta-cell apoptosis and stimulation of insulin production. Elsevier 2020-12 2020-10-09 /pmc/articles/PMC7715050/ /pubmed/33304158 http://dx.doi.org/10.1016/j.sjbs.2020.09.060 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Harakeh, Steve
Almuhayawi, Mohammed
Jaouni, Soad Al
Almasaudi, Saad
Hassan, Saber
Amri, Turki Al
Azhar, Najiah
Abd-Allah, Elham
Ali, Soad
El-Shitany, Nagla
Mousa, Shaker A.
Antidiabetic effects of novel ellagic acid nanoformulation: Insulin-secreting and anti-apoptosis effects
title Antidiabetic effects of novel ellagic acid nanoformulation: Insulin-secreting and anti-apoptosis effects
title_full Antidiabetic effects of novel ellagic acid nanoformulation: Insulin-secreting and anti-apoptosis effects
title_fullStr Antidiabetic effects of novel ellagic acid nanoformulation: Insulin-secreting and anti-apoptosis effects
title_full_unstemmed Antidiabetic effects of novel ellagic acid nanoformulation: Insulin-secreting and anti-apoptosis effects
title_short Antidiabetic effects of novel ellagic acid nanoformulation: Insulin-secreting and anti-apoptosis effects
title_sort antidiabetic effects of novel ellagic acid nanoformulation: insulin-secreting and anti-apoptosis effects
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715050/
https://www.ncbi.nlm.nih.gov/pubmed/33304158
http://dx.doi.org/10.1016/j.sjbs.2020.09.060
work_keys_str_mv AT harakehsteve antidiabeticeffectsofnovelellagicacidnanoformulationinsulinsecretingandantiapoptosiseffects
AT almuhayawimohammed antidiabeticeffectsofnovelellagicacidnanoformulationinsulinsecretingandantiapoptosiseffects
AT jaounisoadal antidiabeticeffectsofnovelellagicacidnanoformulationinsulinsecretingandantiapoptosiseffects
AT almasaudisaad antidiabeticeffectsofnovelellagicacidnanoformulationinsulinsecretingandantiapoptosiseffects
AT hassansaber antidiabeticeffectsofnovelellagicacidnanoformulationinsulinsecretingandantiapoptosiseffects
AT amriturkial antidiabeticeffectsofnovelellagicacidnanoformulationinsulinsecretingandantiapoptosiseffects
AT azharnajiah antidiabeticeffectsofnovelellagicacidnanoformulationinsulinsecretingandantiapoptosiseffects
AT abdallahelham antidiabeticeffectsofnovelellagicacidnanoformulationinsulinsecretingandantiapoptosiseffects
AT alisoad antidiabeticeffectsofnovelellagicacidnanoformulationinsulinsecretingandantiapoptosiseffects
AT elshitanynagla antidiabeticeffectsofnovelellagicacidnanoformulationinsulinsecretingandantiapoptosiseffects
AT mousashakera antidiabeticeffectsofnovelellagicacidnanoformulationinsulinsecretingandantiapoptosiseffects